Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 1/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 14/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19334589 | 0.97 | SLC6A4 (0.39) | SLC6A4SLC6A3HRH3KDM4EALDH1A1 | |
| SCHEMBL3309623 | 0.97 | SLC6A4 (0.39) | SLC6A4SLC6A3HRH3KDM4EALDH1A1 | |
| Water SCHEMBL28471103 | 0.94 | SLC6A3 (0.38) | SLC6A4SLC6A3HRH3KDM4EALDH1A1 | |
| SCHEMBL24740634 | 0.94 | — | — | |
| SCHEMBL8215870 | 0.87 | HRH3 (0.41) | HRH3KDM4EALDH1A1TP53TDP1 | |
| SCHEMBL11570613 | 0.87 | — | — | |
| SCHEMBL10324582 | 0.85 | SLC6A4 (0.34) | SLC6A4SLC6A3HRH3 | |
| SCHEMBL2493041 | 0.84 | SLC6A3 (0.39) | SLC6A4SLC6A3HRH3KDM4EALDH1A1 | |
| SCHEMBL4035791 | 0.84 | SLC6A4 (0.36) | SLC6A4SLC6A3 | |
| SCHEMBL2229569 | 0.84 | SLC6A3 (0.37) | SLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116635228-A | Surface protective film | 日东电工株式会社 | 2023-08-22 | — | — | CN | disclosed |
| WO-2022171128-A1 | PYRAZOLO[3,4-D]PYRIMIDINE-3-KETONE DERIVATIVE SERVING AS WEE-1 INHIBITOR | 微境生物医药科技(上海)有限公司 | 2022-08-18 | — | — | WO | disclosed |
| US-11413682-B2 | Method for producing surface-modified metal oxide fine particle, method for producing improved metal oxide fine particles, surface-modified metal oxide fine particles, and metal oxide fine particle dispersion liquid | TOKYO OHKA KOGYO CO., LTD. (JP) | 2022-08-16 | — | — | US | disclosed |
| US-20200139433-A1 | METHOD FOR PRODUCING SURFACE-MODIFIED METAL OXIDE FINE PARTICLE, METHOD FOR PRODUCING IMPROVED METAL OXIDE FINE PARTICLES, SURFACE-MODIFIED METAL OXIDE FINE PARTICLES, AND METAL OXIDE FINE PARTICLE DISPERSION LIQUID | TOKYO OHKA KOGYO CO., LTD. (JP) | 2020-05-07 | — | — | US | disclosed |
| US-20190070178-A1 | METHODS FOR TREATING OR PREVENTING CARDIOVASCULAR DISORDERS AND LOWERING RISK OF CARDIOVASCULAR EVENTS | DALCOR PHARMA UK LTD., LEATHERHEAD, ZUG BRANCH (CH) | 2019-03-07 | — | — | US | disclosed |
| CN-108727343-A | Quinazolinones PARP-1/2 inhibitor containing 3- amino nafoxidines and preparation method thereof, pharmaceutical composition and purposes | 中国医学科学院药物研究所 | 2018-11-02 | — | — | CN | disclosed |
| CN-108432026-A | The application method of electrolyte composition, secondary cell and secondary cell | 琳得科株式会社 | 2018-08-21 | — | — | CN | disclosed |
| US-9755240-B2 | Electrode for sodium molten-salt battery and sodium molten-salt battery | SUMITOMO ELECTRIC INDUSTRIES, LTD. (JP) | 2017-09-05 | — | — | US | disclosed |
| EP-2632255-B1 | DIAZENIUMDIOLATE HETEROCYCLIC DERIVATIVES | MERCK SHARP & DOHME (US) | 2017-06-21 | — | — | EP | disclosed |
| EP-2958181-B1 | NON-AQUEOUS ELECTROLYTIC SOLUTION AND NON-AQUEOUS ELECTROLYTE SECONDARY BATTERY | MITSUBISHI CHEM CORP (JP) | 2017-06-14 | — | — | EP | disclosed |
| US-7605271-B2 | Superhigh purity ionic liquid | DAI-ICHI KOGYO SEIYAKU CO., LTD (JP) | 2009-10-20 | — | — | US | disclosed |
| US-20090163465-A1 | Pyrimidines as PLK inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-06-25 | — | — | US | disclosed |
| US-20090149438-A1 | Pyrimidines as PLK inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-06-11 | — | — | US | disclosed |
| US-7521457-B2 | Pyrimidines as PLK inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-04-21 | — | — | US | disclosed |
| US-20080161371-A1 | Modulators of cystic fibrosis transmembrane conductance regulator | FIRST-CITIZENS BANK & TRUST COMPANY | 2008-07-03 | — | — | US | disclosed |
| EP-1558600-B1 | SELECTED CGRP ANTAGONISTS, METHOD FOR PRODUCTION AND USE THEREOF AS MEDICAMENT | BOEHRINGER INGELHEIM PHARMA (DE) | 2008-05-07 | — | — | EP | disclosed |
| WO-2008041090-A1 | MALANIN CONCENTRATING HORMONE RECEPTOR-1 ANTAGONIST PYRIDINONES | PFIZER LIMITED (GB) | 2008-04-10 | — | — | WO | disclosed |
| CN-1872935-A | Adhesive composition, adhesive sheet and surface-protective film | NITTO DENKO CORP (JP) | 2006-12-06 | — | — | CN | disclosed |
| US-20060223995-A1 | Superhigh purity ionic liquid | DAI-ICHI KOGYO SEIYAKU CO., LTD. (JP) | 2006-10-05 | — | — | US | disclosed |
| EP-1707265-A1 | Superhigh purity ionic liquid | DAI-ICHI KOGYO SEIYAKU CO., LTD. (JP) | 2006-10-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090163465-A1 | Pyrimidines as PLK inhibitors | PLK2, PLK3, TYMP | SLC6A4 3796/4885SLC6A3 4330/4885HRH3 1935/4885 |
| US-20090149438-A1 | Pyrimidines as PLK inhibitors | PLK2, PLK3, TYMP | SLC6A4 3796/4885SLC6A3 4330/4885HRH3 1935/4885 |
| US-20190070178-A1 | METHODS FOR TREATING OR PREVENTING CARDIOVASCULAR DISORDERS AND LOWERING RISK OF CARDIOVASCULAR EVENTS | HMGCR, PCSK9, FABP3 | SLC6A4 909/4885SLC6A3 1076/4885HRH3 4303/4885 |
| US-20080161371-A1 | Modulators of cystic fibrosis transmembrane conductance regulator | CFTR, SCNN1G, SCNN1B | SLC6A4 1526/4885SLC6A3 1422/4885HRH3 2946/4885 |
| US-20060223995-A1 | Superhigh purity ionic liquid | SLC7A5, SLC7A1, SLC43A1 | SLC6A4 1865/4885SLC6A3 1035/4885HRH3 709/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.